Posts by: Janet Stewart, MSc

Janet Stewart, MSc

Janet Stewart is a life sciences writer and editor, who completed both PhD course work and oral examinations in the Department of Microbiology and Immunology at McGill University, and holds an M.Sc. in Virology and Immunology.

June 8, 2018June 8, 2018

Stelara Reduces Risk of Hospitalization, Surgery for Crohn’s Patients, New Phase 3 Data Show

News

Stelara (ustekinumab) can reduce the risk of Crohn’s disease-related hospitalization and surgery, according to new two-year Phase 3 results announced by Janssen, the therapy’s maker. This new analysis of long-term ... Read more

December 19, 2017December 19, 2017

Study Identifies How Many Missed Doses of Humira or Cimzia Can Cause an IBD Flare-up

News

Inflammatory bowel disease patients taking the biologicals Humira or Cimzia (certolizumab) are at significant risk of flare-ups if they delay refilling their prescriptions for more than two days out of two weeks, ... Read more

December 12, 2017December 12, 2017

New Data Show Kappaproct’s Potential in Treating Ulcerative Colitis

News

Based on newly available data, researchers better understand how the Toll-like receptor 9 (TLR9) agonist Kappaproct (cobitolimod), developed by InDex Pharmaceuticals, can provide anti-inflammatory relief of the clinical symptoms of ulcerative colitis ... Read more

December 5, 2017December 5, 2017

FDA Grants Orphan Drug Status to Seres for Pediatric Ulcerative Colitis Therapy

News

Seres Therapeutics has secured an orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for SER-287, its therapy to treat ulcerative colitis in children. ODD offers companies incentives ... Read more

October 31, 2017

Enterome’s Investigational EB8018 for Crohn’s is Found Safe in Phase 1 Trial

News

Enterome Bioscience’s EB8018, a potential new therapy for Crohn’s disease, was well-tolerated by healthy volunteers in a Phase 1 clinical trial. EB8018 targets the gut microbiome (the gut includes the ... Read more

October 26, 2017October 26, 2017

Researchers Identify Protein Involved in IBD Development

News

Researchers have found a protein called CCDC88B that is present at high levels in the colons of patients with inflammatory bowel disease (IBD). They suggest that this protein plays a ... Read more

September 28, 2017

Wound-Healing Protein May Be Useful in Treating IBS

News

A protein produced by immune cells can promote wound healing in the intestine, a finding that could lead to treatments for inflammatory bowel syndrome (IBS). The study “Macrophage-derived IL-10 mediates ... Read more

August 10, 2017August 18, 2017

Psoriasis Patients in Phase 1 Trial Receiving KY1005-CT01, a Potential Bowel Disease Therapy

Crohn's Disease, News

A 24th psoriasis patient has received KY1005-CT01 in a Phase 1 clinical trial of the treatment designed to fight the autoimmune disorder affecting the skin and other organs. KY1005 has the ... Read more

April 25, 2017April 25, 2017

Renflexis, Biosimilar for Remicade to Treat Crohn’s and UC, Approved by FDA

News

Renflexis (infliximab-abda), a biosimilar of Remicade (infliximab), has been approved in the U.S. to treat a number of autoimmune diseases, including adult and pediatric Crohn’s disease and adult ulcerative colitis. Samsung Bioepis, which ... Read more

March 28, 2017March 28, 2017

Neurological Symptoms of Gulf War Illness Linked to Intestinal Disturbances, Study Suggests

News

Gulf War Illness (GWI) has many symptoms, and now a link between changes in the gut microbiome (bacteria living in the intestines) and neuroinflammation (inflammation of the brain) has been identified, ... Read more